BioCentury | Dec 9, 2002
Clinical News

PCL-016: Phase IIa

...IIa trial of PCL-016, which will be applied topically twice a day for 12 weeks. Novactyl Inc....
BioCentury | Oct 7, 2002
Company News

Novactyl, Upsher-Smith deal

...Upsher-Smith received exclusive worldwide development and marketing rights to Novactyl's PCL-016 and FDR-488 antivirals that target...
...FDR-488 antivirals that target zinc finger proteins (ZFPs) to treat cold sores and genital herpes. Novactyl...
...certain expenses, and is eligible for milestones and royalties. PCL-016 has completed Phase I testing. Novactyl Inc....
BioCentury | May 29, 2001
Clinical News

NVTL0001: Began Phase I trial

...small molecule that disrupts certain viral proteins Indication: Treat herpes labialis End point: Safety Status: Novactyl...
Items per page:
1 - 3 of 3
BioCentury | Dec 9, 2002
Clinical News

PCL-016: Phase IIa

...IIa trial of PCL-016, which will be applied topically twice a day for 12 weeks. Novactyl Inc....
BioCentury | Oct 7, 2002
Company News

Novactyl, Upsher-Smith deal

...Upsher-Smith received exclusive worldwide development and marketing rights to Novactyl's PCL-016 and FDR-488 antivirals that target...
...FDR-488 antivirals that target zinc finger proteins (ZFPs) to treat cold sores and genital herpes. Novactyl...
...certain expenses, and is eligible for milestones and royalties. PCL-016 has completed Phase I testing. Novactyl Inc....
BioCentury | May 29, 2001
Clinical News

NVTL0001: Began Phase I trial

...small molecule that disrupts certain viral proteins Indication: Treat herpes labialis End point: Safety Status: Novactyl...
Items per page:
1 - 3 of 3